CLLS
$3.34-0.14 (-4.02%)
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
Recent News
Cellectis SA (CLLS) Q4 2025 Earnings Call Highlights: Promising Clinical Progress and Strategic ...
Cellectis SA (CLLS) reports strong clinical trial results and effective cash management, positioning itself for future growth despite industry challenges.
European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading; Drop Over 2% for Week
European equities traded in the US as American depositary receipts were sharply lower late Friday mo
What To Expect From Cellectis SA (XPAR:ALCLS) Q4 2025 Earnings
This article first appeared on GuruFocus. Cellectis SA (XPAR:ALCLS) is set to release its Q4 2025 earnings on Mar 20, 2026. The consensus estimate for Q4 2025 revenue is $14.90 million, and the earnings are expected to come in at -$0.24 per share.
European Equities Traded in US as ADRs Fall in Wednesday Trading
European equities traded in the US as American depositary receipts fell late Wednesday morning with
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
European equities traded in the US as American depositary receipts were lower late Friday morning, d